Moolec Science Announces Successful Closing of Business Combination, Expanding Across Life Sciences and Food-Tech
- Strategic merger creates a diversified life sciences platform combining molecular farming, precision fermentation, and agricultural biologicals
- Strong shareholder approval with 98% votes in favor of the transaction
- Appointment of experienced CEO Alejandro Antalich with proven M&A track record and $300M exit experience
- Integration of multiple revenue-generating brands and technologies including Piggy Sooy, GLASO, Mycofood, Rizobacter, ProFarm, and HB4
- Enhanced R&D capabilities through Agrality and Synbio Powerlabs platforms
- Significant integration challenges ahead combining multiple companies and technologies
- Share dilution from issuing approximately 7.55M new shares to acquisition targets
- Execution risks in managing diverse business segments across different technology platforms
- Potential organizational complexity from managing multiple brands and subsidiaries
Insights
Moolec's strategic merger creates a comprehensive life science platform with expanded capabilities across sustainable food and agriculture technologies.
Moolec Science has successfully completed a significant business combination that transforms it from a focused food ingredient company into a diversified life sciences platform. The merger with Bioceres Group, Gentle Technologies, and Nutrecon received overwhelming shareholder approval with
The transaction's structure reveals its strategic importance: Bioceres Group shareholders received approximately 6.9 million Moolec shares, while Nutrecon and Gentle Tech shareholders received about 0.65 million shares plus 0.5 million private warrants with a
Particularly noteworthy is how this combination creates an integrated technology stack spanning the entire value chain:
- Upstream agricultural technologies (biological inputs and climate-smart seeds)
- Molecular farming and precision fermentation capabilities
- R&D infrastructure through Agrality® and Synbio Powerlabs®
- Downstream ingredient brands including Piggy Sooy™, GLASO™, and Mycofood™
The appointment of Alejandro Antalich as CEO brings valuable experience in both scaling sustainable technologies and executing strategic transactions, including a previous
This transaction represents a significant strategic expansion that strengthens Moolec's competitive positioning in the rapidly growing sustainable food and agriculture technology sectors by creating a comprehensive platform with capabilities spanning from molecular development to commercial ingredients.
GRAND CAYMAN, CAYMAN ISLANDS / ACCESS Newswire / June 17, 2025 / Moolec Science SA (NASDAQ:MLEC) ("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced the successful closing of its previously announced strategic business combination (the "Business Combination") with Bioceres Group Limited ("Bioceres Group"), Gentle Technologies Corp ("Gentle Tech"), and Nutrecon LLC ("Nutrecon"). With the closing, Moolec emerges as the parent company of a significantly expanded and enhanced enterprise at the forefront of sustainable life sciences and food-tech innovation.
This transformative transaction brings together complementary capabilities across food ingredients, ag-biologicals, precision fermentation, biomaterials, and R&D services, consolidating Moolec's position as a differentiated life science platform focused on sustainable solutions from molecule to ingredient.
The Business Combination, initially announced on April 17, 2025, was ratified by Moolec shareholders at the Extraordinary General Meeting ("EGM") held on June 16, with ~
Under the terms of the transaction, Bioceres Group shareholders have exchanged their equity ownership for approximately 6.9 million shares of Moolec. The shareholders of
The combined company will continue operating under the name Moolec Science, with its securities trading on NASDAQ under the ticker symbols "MLEC" and "MLECW".
The Board of Directors has appointed Mr. Alejandro Antalich as Chief Executive Officer of Moolec Science. Mr. Antalich brings over 20 years of international leadership experience in biotechnology and life sciences, with a proven track record of scaling sustainable technologies, driving strategic partnerships, M&A, and delivering significant growth through value-creating transactions. Prior to this appointment, he served as CEO of Nutrecon, where he positioned the company as a key innovator in precision fermentation and alternative protein ingredients, and established a state-of-the-art synthetic biology platform providing integrated R&D, contract development, and manufacturing services. Earlier in his career, he led an innovative life sciences company, guiding its international expansion and executing its strategic sale to a global publicly traded corporation in a landmark transaction valued at nearly
Key highlights:
Ingredient Innovation: Moolec will continue advancing its flagship molecular farming products, such as Piggy Sooy™ and GLASO™, while integrating Mycofood™ - acquired through Nutrecon - under the Eternal® brand to expand its alternative protein offering.
Biological Ag Expansion: Through Bioceres Group, Moolec will now offer upstream technologies for regenerative agriculture, including biological inputs and climate-smart seeds under the Rizobacter®, ProFarm®, and HB4® brands.
Integrated R&D and Technical Capabilities: With cutting-edge infrastructure through Agrality® and Synbio Powerlabs® - platforms belonging to Bioceres Group and Nutrecon, respectively - Moolec now benefits from in-house R&D, CDMO and regulatory capabilities designed to accelerate the development, testing, and regulatory progression of its technology pipeline.
Emerging Tech & Equipment: The Company will also expand its presence in emerging technologies for grain and biomass transformation, particularly within the biomaterials space, as well as new concepts in farm equipment that integrate material science, electric mobility, and autonomy. These initiatives are currently being developed through subsidiaries of Gentle Tech and Bioceres Group.
Forward Looking Statements
This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
Contact Information
Press & Media
comms@moolecscience.com
Investor Relations
ir@moolecscience.com
SOURCE: Moolec Science SA
View the original press release on ACCESS Newswire
FAQ
What companies did Moolec Science (MLEC) acquire in its business combination?
How many shares did Moolec Science issue for the business combination?
Who is the new CEO of Moolec Science after the merger?
What are the main brands and products in Moolec's expanded portfolio?
What was the shareholder approval rate for Moolec's business combination?
